Skip main navigation (Press Enter).

FDA Pushes Risk-Based Approach to Nanomaterial Drugs

Share:

December 20, 2017

FDA Pushes Risk-Based Approach to Nanomaterial Drugs

Developers of drugs containing nanomaterials—substances so small they cannot be seen with a regular microscope—got some advice on how to assess their risks in the Food and Drug Administration (FDA) draft guidance issued on Dec. 15.

Related Stories

Get Involved! Volunteer for the New Regulatory Response Subcommittee

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Raw Material Variability and Classification – Thinking beyond the Regulatory Submission

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Regulatory Developments September 2023

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Regulatory Developments August 2023

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Regulatory Developments June 2023

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

«
1
2
3
4
5
...
»

Contact Us:

Kristen Kalmann, Content Manager
2107 Wilson Blvd. Ste. 200
Arlington, VA 22201

Advertising

View the Media Kit

AAPS Customer Service

1-703-243-2800

Copyright © 2024 AAPS Newsmagazine. All rights reserved.

Powered by Higher Logic

Global message icon